Cryo Cell International Free Cash Flow (FCF) History (CCEL)
Cryo Cell International reported $5.2M in free cash flow for fiscal 2025, an increase of 45.49% from the previous fiscal year, with a free cash flow margin of 16.63%.
View full Cryo Cell International company overviewCryo Cell International free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-11-30 | $5.2M | $1.6M | +45.49% | +16.63% |
| 2024 | 2024-11-30 | $3.6M | $1.5M | +73.36% | +11.28% |
| 2023 | 2023-11-30 | $2.1M | $5.7M | — | +6.64% |
| 2022 | 2022-11-30 | −$3.6M | −$9.7M | — | −11.85% |
| 2021 | 2021-11-30 | $6.1M | −$2.3M | −27.19% | +21.09% |
| 2020 | 2020-11-30 | $8.4M | $2.7M | +48.54% | +26.86% |
| 2019 | 2019-11-30 | $5.6M | $745,381 | +15.25% | +17.70% |
| 2018 | 2018-11-30 | $4.9M | −$732,673 | −13.04% | +16.73% |
| 2017 | 2017-11-30 | $5.6M | $974,847 | +20.99% | +22.14% |
| 2016 | 2016-11-30 | $4.6M | −$97,989 | −2.07% | +20.08% |
| 2015 | 2015-11-30 | $4.7M | $3.3M | +230.68% | +22.49% |
| 2014 | 2014-11-30 | $1.4M | $962,108 | +203.75% | +7.13% |
| 2013 | 2013-11-30 | $472,196 | $244,833 | +107.68% | +2.49% |
| 2012 | 2012-11-30 | $227,363 | −$86,044 | −27.45% | +1.27% |
| 2011 | 2011-11-30 | $313,407 | −$1.6M | −83.84% | +1.75% |
| 2010 | 2010-11-30 | $1.9M | — | — | +10.92% |
Cryo Cell International quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $1.8M | $1.2M | +181.29% | +23.32% |
| Q1 2026 | 2026-02-28 | $584,762 | −$307,248 | −34.44% | +7.61% |
| Q4 2025 | 2025-11-30 | $1.2M | −$935,058 | −43.52% | +15.47% |
| Q3 2025 | 2025-08-31 | $2.5M | $246,333 | +10.94% | +31.92% |
| Q2 2025 | 2025-05-31 | $644,606 | $623,057 | +2891.35% | +8.13% |
| Q1 2025 | 2025-02-28 | $892,010 | $1.7M | — | +11.19% |
| Q4 2024 | 2024-11-30 | $2.1M | $519,244 | +31.87% | +26.78% |
| Q3 2024 | 2024-08-31 | $2.3M | $3.6M | — | +27.91% |
| Q2 2024 | 2024-05-31 | $21,549 | −$510,108 | −95.95% | +0.27% |
| Q1 2024 | 2024-02-29 | −$814,587 | −$2.1M | — | −10.37% |
| Q4 2023 | 2023-11-30 | $1.6M | −$775,324 | −32.24% | +20.69% |
| Q3 2023 | 2023-08-31 | −$1.3M | $7.2M | — | −17.14% |
| Q2 2023 | 2023-05-31 | $531,657 | −$1.1M | −67.59% | +6.84% |
| Q1 2023 | 2023-02-28 | $1.3M | $409,204 | +47.63% | +16.21% |
| Q4 2022 | 2022-11-30 | $2.4M | $1.0M | +73.32% | +30.97% |
| Q3 2022 | 2022-08-31 | −$8.5M | −$9.1M | — | −111.31% |
| Q2 2022 | 2022-05-31 | $1.6M | $113,426 | +7.43% | +21.49% |
| Q1 2022 | 2022-02-28 | $859,122 | −$1.8M | −67.58% | +11.84% |
| Q4 2021 | 2021-11-30 | $1.4M | −$1.5M | −52.63% | +18.97% |
| Q3 2021 | 2021-08-31 | $527,737 | −$1.5M | −74.26% | +7.03% |
| Q2 2021 | 2021-05-31 | $1.5M | $747,889 | +96.02% | +21.19% |
| Q1 2021 | 2021-02-28 | $2.7M | $41,462 | +1.59% | +38.63% |
| Q4 2020 | 2020-11-30 | $2.9M | $2.0M | +202.13% | +38.85% |
| Q3 2020 | 2020-08-31 | $2.0M | −$640,246 | −23.80% | +25.26% |
| Q2 2020 | 2020-05-31 | $778,925 | $611,030 | +363.94% | +9.90% |
| Q1 2020 | 2020-02-29 | $2.6M | $803,645 | +44.52% | +34.23% |
| Q4 2019 | 2019-11-30 | $969,495 | $163,373 | +20.27% | +12.16% |
| Q3 2019 | 2019-08-31 | $2.7M | $79,347 | +3.04% | +32.71% |
| Q2 2019 | 2019-05-31 | $167,895 | $135,863 | +424.15% | +2.07% |
| Q1 2019 | 2019-02-28 | $1.8M | $366,798 | +25.50% | +24.08% |
| Q4 2018 | 2018-11-30 | $806,122 | −$1.3M | −61.03% | +9.38% |
| Q3 2018 | 2018-08-31 | $2.6M | $1.4M | +122.51% | +33.17% |
| Q2 2018 | 2018-05-31 | $32,032 | −$1.9M | −98.36% | +0.49% |
| Q1 2018 | 2018-02-28 | $1.4M | $1.0M | +237.49% | +23.09% |
| Q4 2017 | 2017-11-30 | $2.1M | — | — | +31.95% |
| Q3 2017 | 2017-08-31 | $1.2M | $99,623 | +9.28% | +17.01% |
| Q2 2017 | 2017-05-31 | $2.0M | — | — | +31.30% |
| Q1 2017 | 2017-02-28 | $426,138 | $355,444 | +502.79% | +7.38% |
| Q3 2016 | 2016-08-31 | $1.1M | $55,648 | +5.47% | +16.96% |
| Q1 2016 | 2016-02-29 | $70,694 | −$234,967 | −76.87% | +1.37% |
| Q4 2015 | 2015-11-30 | $1.9M | $1.7M | +795.26% | +33.36% |
| Q3 2015 | 2015-08-31 | $1.0M | $88,037 | +9.47% | +18.73% |
| Q2 2015 | 2015-05-31 | $1.5M | $1.1M | +265.83% | +29.62% |
| Q1 2015 | 2015-02-28 | $305,661 | $423,382 | — | +6.31% |
| Q4 2014 | 2014-11-30 | $216,046 | $348,294 | — | +4.34% |
| Q3 2014 | 2014-08-31 | $930,033 | $1.2M | — | +18.83% |
| Q2 2014 | 2014-05-31 | $405,946 | −$24,699 | −5.74% | +8.30% |
| Q1 2014 | 2014-02-28 | −$117,721 | −$546,103 | — | −2.21% |
| Q4 2013 | 2013-11-30 | −$132,248 | −$449,413 | — | −2.81% |
| Q3 2013 | 2013-08-31 | −$254,583 | −$707,374 | — | −5.27% |
| Q2 2013 | 2013-05-31 | $430,645 | $1.1M | — | +8.86% |
| Q1 2013 | 2013-02-28 | $428,382 | $349,716 | +444.56% | +9.31% |
| Q4 2012 | 2012-11-30 | $317,165 | $12,513 | +4.11% | +6.58% |
| Q3 2012 | 2012-08-31 | $452,791 | $429,652 | +1856.83% | +9.97% |
| Q2 2012 | 2012-05-31 | −$629,539 | −$497,541 | — | −14.23% |
| Q1 2012 | 2012-02-29 | $78,666 | $70,510 | +864.52% | +1.88% |
| Q4 2011 | 2011-11-30 | $304,652 | — | — | +6.87% |
| Q3 2011 | 2011-08-31 | $23,139 | — | — | +0.52% |
| Q2 2011 | 2011-05-31 | −$131,998 | — | — | −2.87% |
| Q1 2011 | 2011-02-28 | $8,156 | — | — | +0.18% |
Cryo Cell International free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $8.4M to $5.2M, a compound annual decline of 8.91%. Cryo Cell International's latest reported quarter, Q2 2026, generated $1.8M in free cash flow, an increase of 181.29% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Cryo Cell International source filings ↗